These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 31124334)

  • 1. Assessing the Optimal Cutpoint for Tumor Size in Patients with Lung Cancer Based on Linear Rank Statistics in a Competing Risks Framework.
    Kim J; Ng HKT; Kim SW
    Yonsei Med J; 2019 Jun; 60(6):517-524. PubMed ID: 31124334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis.
    Faraggi D; Simon R
    Stat Med; 1996 Oct; 15(20):2203-13. PubMed ID: 8910964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalized maximally selected statistics.
    Hothorn T; Zeileis A
    Biometrics; 2008 Dec; 64(4):1263-9. PubMed ID: 18325074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A likelihood and resampling based approach to dichotomizing a continuous biomarker in medical research.
    Su M; Fang L; Su Z
    J Biopharm Stat; 2013 May; 23(3):637-47. PubMed ID: 23611200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Permutation-based variance component test in generalized linear mixed model with application to multilocus genetic association study.
    Zeng P; Zhao Y; Li H; Wang T; Chen F
    BMC Med Res Methodol; 2015 Apr; 15():37. PubMed ID: 25897803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A sample size formula for the supremum log-rank statistic.
    Eng KH; Kosorok MR
    Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rank-based permutation approaches for non-parametric factorial designs.
    Umlauft M; Konietschke F; Pauly M
    Br J Math Stat Psychol; 2017 Nov; 70(3):368-390. PubMed ID: 28295183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mortality in early-stage, surgically resected non-small cell lung cancer less than 3 cm of size: Competing risk analysis].
    Jordá Aragón C; Peñalver Cuesta JC; Mancheño Franch N; de Aguiar Quevedo K; Vera Sempere F; Padilla Alarcón J
    Med Clin (Barc); 2015 Sep; 145(5):185-91. PubMed ID: 25433784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the importance of accounting for competing risks in pediatric cancer trials designed to delay or avoid radiotherapy: I. Basic concepts and first analyses.
    Tai BC; Grundy RG; Machin D
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1493-9. PubMed ID: 19577860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of constrained randomization for the design and analysis of group-randomized trials.
    Li F; Lokhnygina Y; Murray DM; Heagerty PJ; DeLong ER
    Stat Med; 2016 May; 35(10):1565-79. PubMed ID: 26598212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finding differentially expressed genes in high dimensional data: Rank based test statistic via a distance measure.
    Mathur S; Sadana A
    Stat Methods Med Res; 2015 Dec; 24(6):968-79. PubMed ID: 22240308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypothesis test for causal mediation of time-to-event mediator and outcome.
    Huang YT
    Stat Med; 2022 May; 41(11):1971-1985. PubMed ID: 35172384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism.
    Parpia S; Julian JA; Thabane L; Lee AY; Rickles FR; Levine MN
    Contemp Clin Trials; 2011 Nov; 32(6):829-33. PubMed ID: 21777700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive design: estimation and inference with censored data in a semiparametric model.
    Shen Y; Cheng Y
    Biostatistics; 2007 Apr; 8(2):306-22. PubMed ID: 16787996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New methods for multiple testing in permutation inference for the general linear model.
    Mrkvička T; Myllymäki M; Kuronen M; Narisetty NN
    Stat Med; 2022 Jan; 41(2):276-297. PubMed ID: 34687243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
    Mangona VS; Aneese AM; Marina O; Hymas RV; Ionascu D; Robertson JM; Gallardo LJ; Grills IS
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):124-32. PubMed ID: 25442337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of null statistics in permutation-based multiple testing for multi-factorial microarray experiments.
    Gao X
    Bioinformatics; 2006 Jun; 22(12):1486-94. PubMed ID: 16574697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cause-specific quantile residual life regression.
    Lim JY; Jeong JH
    Stat Methods Med Res; 2017 Aug; 26(4):1912-1924. PubMed ID: 26113385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.